Table 2.
Review of the literature: Clinical studies in VKC.
| Study reference (first author, year) | No. of patients | Age in years/sex (M/F) | Atopic comorbidity | Omalizumab dose | Treatment duration | Outcome/control of VKC |
|---|---|---|---|---|---|---|
| Retrospective analyses | ||||||
| Rossberg, 20202 | 3 | 10/M | Allergic rhinoconjunctivitis and asthma | 300 mg/2 weeks | 11 months | Total control in all 3 patients |
| 6/M | Allergic rhinoconjunctivitis | Maximum of 300 mg/4 weeks | 7 months (across 3 years) | |||
| 7/M | Allergic rhinoconjunctivitis, AD, and asthma | 300 mg/2 weeks | 6 months | |||
| Doan, 201957 | 5 | 6−13/M | All had asthma and rhinitis; 4 had eczema | 450−600 mg/2 weeks | >12 months | Total control: 1 patient Partial control: 3 patients No control: 1 patient |
| Coutu, 201957 | 10 | 7−19/9 M and 1 F | 9 patients sensitized to airborne allergens and 4 to food allergens | Based on weight and total serum IgE levels | Not available (mean ± SD follow-up after first injection: 62.9 ± 33.85 weeks) | This was a QoL study. Total control (no corneal ulcers during the treatment period) with good QoL improvements in all 10 patients |
| Doan, 201632 | 4 | 7−13/M | All had asthma and 1 had severe eyelid eczema | 450–600 mg/2 weeks | Median: 33 months in 3 patients | Total control: 3 patients No control: 1 patient (treatment discontinued) |
| Case series | ||||||
| Silva, 201960 | 3 | 6/M 23/F 15/M |
All patients had severe asthma and allergic rhinitis | Regular dosing for asthma | 180 days | Total control in all 3 patients |
| Occasi, 201759 | 4 | 6/M | Eczema in 1 patient and persistent rhinitis in 2 patients | 225 mg/2 weeks | 6 months | Total control in all 4 patients |
| 8/M | 300 mg/4 weeks | |||||
| 11/F | 225 mg/4 weeks | |||||
| 9/M | 225 mg/4 weeks | |||||
| Case reports | ||||||
| Zengarini, 202261 | 1 | 13/M | Severe AD | 300 mg/month | 3 months (ongoing) | Total control |
| Manti, 20211 | 2 | 12/M | Severe allergic asthma | 450 mg/2 weeks | 9 months | Total control in both patients |
| 10/M | 600 mg/2 weeks | |||||
| Tardino, 202062 | 2 | 13/NA | Asthma | Based on weight; every 2 weeks | 16 weeks | Total control in both patients |
| 10/NA | ||||||
| Limao, 202063 | 2 | 17/M | Eczema and allergic rhinitis | Dosing details NA | 5 years | Total control in both patients |
| 10/M | Eczema, allergic rhinitis, and asthmaweeks | 10 months (ongoing) | ||||
| Simpson, 201964 | 1 | 54/M | Seasonal allergic rhinoconjunctivitisweeks | 300 mg | Single dose | Total control |
| Santamaria, 201865 | 1 | 15/F | Rhinitis | 225 mg/2 weeks, reduced to 150 mg/2 weeks after 24 monthsweeks | 54 months | Total control, with relapse upon discontinuation |
| Picardi, 201666 Heffler, 201654 |
2 | 9/F | None | 300 mg/month | 6 months | Total control |
| 21/M | AD | 600 mg/month | Partial control | |||
| Occasi, 201567 | 1 | 15/M | Asthma and AD | 600 mg/2 weeks | 3 months | Total control |
| de Klerk, 201356 | 1 | 12/M | Allergic asthma, severe rhinoconjunctivitis, and eczema | 300 mg/month | 18 months | Total control |
| Sanchez, 20123 | 1 | 15/M | Asthma, rhinitis, and AD | 300 mg/2 weeks | 9 months | Total control |
| Williams, 200537 | 3 | 33/M | Asthma, rhinitis, and AD | Based on weight and total serum IgE levels | Not specified | Total control |
| 67/F | No changes | |||||
| 59/F | Total control |
AD, atopic dermatitis; F, female; IgE, immunoglobulin E; M, male; NA, not available; QoL, quality of life; SD, standard deviation; VKC, vernal keratoconjunctivitis